- Home
- Product Candidates
- Sepsis
RECCE® 327 I.V.
RECCE® 327 (R327) was developed beginning with the end in mind, being entirely synthesised to capture and enhance unique mechanisms of action, able to overcome deadly viral and bacterial infections, including the full suite of ESKAPE pathogens, even in their multi-drug resistant forms.
Overview
Sepsis, is a life-threatening inflammatory response to infection that has spread to the body. There is no universal treatment for the disease – with the current standard of care being the immediate administration of multiple antibiotics through an intravenous (IV) infusion. Approximately 1/3 patients present unspecific symptoms, leading to delayed treatment and a high mortality rate – 8% increase for every hour left untreated.
Therefore, early treatment with an effective antibiotic is key to the patients’ outcome.
Sepsis Cases and Fatalities by Geographical Area
Worldwide
Cases
47-50 million
11 million
deaths annually
USA
Cases
1.7 million
270,000
deaths annually
Europe
Cases
3.4 million
700,000
deaths annually
Australia
Cases
50,000
8,700
deaths annually
Sepsis Patient Journey
Patient Presents to Hospital
- 1/3 of patients present non-specific symptoms, leading to delayed treatment and high mortality rate.
- Mortality from sepsis increases by as much as 8% for every hour that treatment is delayed.
- Cost of sepsis care for inpatient admissions and skilled nursing facility: in-patient rehab medical treatment centre admissions was more than USD $62bn/yr (USD $170m/day).
Current Treatment Paradigm
- Introducing broad-spectrum antibiotic(s)
- Running antibiograms
- Adjusting antibiotics based on antibiogram results
Introducing R327 as the potential solution
Early treatment with an effective antibiotic is key to improving patient outcome.
Helpful Sites
The UK Sepsis Trust
Global Sepsis Alliance
Pew
World Sepsis Day
Australian Sepsis Network
Clinical Excellence Commission
Sepsis Alliance
